Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 27;60(1):535–542. doi: 10.1080/13880209.2022.2042327

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — NLRP3 agonist nigericin eliminated the protective effect of SenA on chondrocytes. (A, B) Nigericin enhanced the protein expression of NLRP3 signalling pathway-related proteins (NLRP3, ASC and caspase-1) in IL-1β-stimulated chondrocytes. (C, D) Nigericin enhanced the expression of catabolic marker proteins (MMP13, ADAMTS4/5) in IL-1β-stimulated chondrocytes. (E, F) Nigericin inhibited the expression of anabolic marker proteins (IGF-1, aggrecan and Col2a1) in IL-1β-stimulated chondrocytes. (G) Nigericin inhibited cell proliferation of chondrocytes. (H) Nigericin promoted cell apoptosis of chondrocytes. *p < 0.05 compared with control (con) group; ^#p < 0.05 compared with IL-1β group; ^&p < 0.05 compared with IL-1β + SenA group.